BIIB News 304.79 06/18/2014 04:31:32 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 304.79 $BIIB

Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Tue Jun 17, 3:55PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $302.01 to a high of $307.46. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $306.40 on volume of 857,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.03%
Comtex SmarTrend(R) - Tue Jun 17, 3:55PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $302.01 to a high of $307.46. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $306.40 on volume of 857,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

2 Exciting Developments for Biogen Idec Inc.
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 17, 8:02AM CDT
Biogen , which just got nod from the FDA for its potential blockbuster hemophilia drug Eloctate last week, has also now cleared a major hurdle for a drug in its multiple sclerosis franchise. Joint developers Biogen and AbbVie announced Monday...

True North Therapeutics Announces $22 Million Series A Financing
Business Wire - Tue Jun 17, 6:00AM CDT
True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, announced today that it has completed a $22 million Series A equity financing. Proceeds from the financing will be used to advance True North's lead drug candidate, TNT009, into clinical development, with the initiation of the first human clinical trial planned for early 2015. The total Series A round encompasses initial funds from the spin-out of True North Therapeutics from iPierian, Inc., announced in September 2013. Investors in the Series A financing include Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures, and Baxter Ventures.

Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec
PR Newswire - Tue Jun 17, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder. This is the first milestone payment under Isis' and Biogen Idec's 2013 strategic collaboration to advance the treatment of neurological disorders. This collaboration combines Biogen Idec's expertise in neurology with Isis' leadership in antisense technology to develop novel therapies to treat neurological disorders and is the fourth collaboration between the two companies.

Our Drug Works! But There's a Catch ...
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 16, 5:21PM CDT
AFFiRiS' press release read like a monumental scientific discovery: Breakthrough in Alzheimer's disease: AFFiRiS halted clinical progression in Alzheimer patients upon treatment with AD04 in a phase II clinical study There's just one catch:...

Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
Business Wire - Mon Jun 16, 6:30AM CDT
--a^' Positive Results Set Stage for Regulatory Filings -

Sobi to review preclinical data to potentially add future haemophilia A candidate to collaboration agreement with Biogen Idec
Thomson Reuters ONE - Mon Jun 16, 1:01AM CDT
On Friday, 13 June, Swedish Orphan Biovitrum AB's (publ) (Sobi) received a data package from Biogen Idec regarding a preclinical Hemophilia A program based on Amunix's proprietary XTEN technology. Amunix and Biogen Idec signed a worldwide license agreement in April 2014. Under the terms of Sobi and Biogen Idec's agreement, Sobi has the right to elect to obtain an option to add potential additional Factor VIII:Fc Constructs to the collaboration. Sobi has 120 days to review the preclinincal data, and to determine whether to elect to obtain such option under the collaboration. If Sobi elects to aquire its option, the company will be required to make a payment to Biogen Idec.

50-Day Moving Average Can Buffer A Strong Stock's Advance
at Investor's Business Daily - Fri Jun 13, 4:27PM CDT
It's frustrating to miss a heavy-volume breakout . The good thing is that the market likes to give second chances. If it's a truly a strong stock and the market is in a healthy uptrend, there will be plenty of other opportunities to buy it. The...

One Year Post-Launch, All Surveyed U.S. Neurologists Report Having Clinical Experience with Biogen Idec's Tecfidera for the Treatment of Multiple Sclerosis
PR Newswire - Thu Jun 12, 11:00AM CDT
Decision Resources Group finds that, within one year of commercial availability, 100 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their multiple sclerosis (MS) patients, far surpassing the one-year trial rate for Genzyme's Aubagio (69 percent) and Novartis's Gilenya (79 percent), despite the fact that Tecfidera is the third-to-market oral disease-modifying therapy (DMT) for MS. Driven by significant increases wave over wave, neurologist-reported Tecfidera patient share among DMT-treated relapsing-remitting MS (RR-MS) patients has grown to 13 percent and now exceeds that reported for Aubagio and Gilenya combined. Among high Tecfidera prescribers, Tecfidera is anticipated to become the RR-MS patient share leader as it will overtake Teva's Copaxone within the next six months.

3 Reasons to Watch Array Biopharma Inc.
Nathaniel Calloway, The Motley Fool - Motley Fool - Thu Jun 12, 9:56AM CDT
It is no secret that the risks associated with pharmaceutical development are considerable. The cost to develop a novel drug often exceeds $1 billion.  Many smaller biotechs support these high development costs by by offering licensing options to...

Watch for Biogen Idec to Potentially Rebound After Falling 1.50% Yesterday
Comtex SmarTrend(R) - Wed Jun 11, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $308.00 to a high of $314.99. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $312.61 on volume of 884,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 11, 11:16AM CDT
The week so far has been highly eventful

FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
PR Newswire - Wed Jun 11, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.

RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology
Business Wire - Wed Jun 11, 4:00AM CDT
Rainbow Coral Corp. (OTCBB: RBCC) received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused.

Why the Future Is Bright for Isis Pharmaceuticals
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 10, 5:30PM CDT
Isis Pharmaceuticals shares have surged this past week on news that it has received two milestone payments for advancing new drugs into phase 1 trials. Those milestone payments from Biogen   and AstraZeneca   successfully shifted attention away...

Up 37%: Can Receptos Compete With Novartis?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 10, 5:15PM CDT
Receptos  shareholders had a great day today, with the stock up 37% on exciting phase 2 data for its lead drug candidate RPC1063 in multiple sclerosis. And with a phase 3 trial pitting RPC1063 against Biogen Idec 's Avonex ongoing, there is some...

Can Receptos' New Drug Beat Biogen?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
Receptos shares surged by a 36% this morning following news that the company's RPC1063 met its primary endpoint as a treatment for relapsing multiple sclerosis. The midstage trial results offer investors hope that Receptos' product will...

Isis Pharma Earns Milestone Payment on Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 10:30AM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a milestone payment of $14 million from Biogen with the initiation of a phase I study on ISIS-DMPKRx for the treatment of myotonic dystrophy type I (DM1).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 121

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 110

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 65

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 115

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Everyday Dose Tests Coffee in a New Pocket Format Today

Updated Category News Views 0

Coffee has finally wandered into the candy aisle, and I cannot decide whether that is clever or mildly exhausting. Everyday Dose and Austin-based Le Lick have launched Le Latte, a limited-batch coffee-flavored electrolyte lollipop aimed at adults who want caffeine without hauling around a cup. It is an odd little product, sure, but odd is often where consumer brands find...

Continue Reading
Mile High Labs Moves CBD Isolate Into FDA DMF Pathway

Updated Category News Views 39

A Quiet Filing With Real Commercial Weight Cannabis headlines usually arrive wearing a clown suit; this one showed up with paperwork. Mile High Labs says it filed Type II Drug Master File No. 044151 with the U.S. Food and Drug Administration for a 98% CBD isolate on October 2, 2026. That is not a product approval, not permission to market a CBD drug, and certainly not a...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 122

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Home Values Need More Than an Algorithm and Hope Today

Updated Category News Views 28

A house can look like a clean number on a screen right up until an actual buyer walks through it and notices the tired roof, the sharp kitchen remodel, or the traffic rattling past the front door. That gap between a digital estimate and a real transaction is the whole point of the recent HelloNation discussion featuring Lawton, Oklahoma, real estate experts Pam Marion and...

Continue Reading
RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 60

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 10

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading

Top 5 Most Recently Viewed Articles

Aris Mining's Q3 2025 Financial Results Announcement

Updated Category News Views 203

Aris Mining's Q3 2025 Earnings Release Announcement Aris Mining Corporation, known for its commitment to becoming a leading force in the Latin American gold mining sector, has announced its Q3 financial results will be disclosed following market close. This exciting update indicates the company's ongoing transparency and dedication to its stakeholders. Details of the...

Continue Reading
eMazzanti Technologies Celebrates New Office with Ribbon-Cutting

Updated Category News Views 104

eMazzanti Technologies Expands with New Office Space eMazzanti Technologies, a leading Managed Services Provider and Cybersecurity firm, has proudly announced the opening of its new, expansive office located at 724 Clinton Street. This new state-of-the-art office symbolizes their commitment to innovation in technology and workplace solutions. Grand Opening Celebration The...

Continue Reading
Understanding AMC Entertainment's Current Short Interest Trends

Updated Category News Views 969

Understanding AMC Entertainment's Short Interest Trends AMC Entertainment Holdings Inc (NYSE: AMC) has witnessed a notable decline in its short percent of float, dropping 18.42% since its last report. The company recently disclosed that it currently has 37.77 million shares sold short, translating to 9.92% of all available trading shares. Given the stock’s trading...

Continue Reading
Unlocking Asset Growth: CoinEx Launches New Staking Service

Updated Category News Views 83

New Possibilities for CET Holders CoinEx, a global cryptocurrency exchange, has rolled out a Staking service that lets you earn rewards by staking your crypto. With staking, you don’t just collect on-chain rewards—you also help secure the underlying blockchain networks. For many, it’s a practical alternative to traditional investing, with a clear, crypto-native way...

Continue Reading
Market Dynamics: Insights from Experts on Investment Strategies

Updated Category News Views 177

Understanding the Current Market Landscape In today's dynamic market, investors often find themselves seeking clarity in uncertain times. Expert analysts are noting a potential for a significant stock market correction, with some indicating probabilities as high as 30%. This perspective challenges the common assumptions held by many retail investors. The Case for Market...

Continue Reading